clinical trial · NCT02833610
A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency
Multiple MyelomaDenosumab Q4W
brief summary
This research study is studying a possible therapy as a possible treatment for the consequences of Multiple Myeloma with renal insufficiency.
started
Aug 1, 2016
primary completion
Mar 20, 2023
completion
Mar 20, 2023
last updated
Feb 18, 2026
detailed description
This research study is a Phase II clinical trial. This study will assess the safety and tolerability of denosumab in Multiple Myeloma participants, by studying drug interactions with different parts of the body.
The FDA (the U.S. Food and Drug Administration) has not approved Denosumab for this specific disease but it has been approved denosumab for use in other cancers to treat cancer-related bone disease such as prostate and breast cancer.
official title
A Phase 2, Single-Arm Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol